(NASDAQ: ARGX) Argenx Se's forecast annual revenue growth rate of 976.47% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.79%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.73%.
Argenx Se's revenue in 2025 is $4,726,086.On average, 11 Wall Street analysts forecast ARGX's revenue for 2025 to be $222,641,149,293, with the lowest ARGX revenue forecast at $209,509,855,832, and the highest ARGX revenue forecast at $239,951,095,289. On average, 11 Wall Street analysts forecast ARGX's revenue for 2026 to be $287,969,082,104, with the lowest ARGX revenue forecast at $236,736,233,054, and the highest ARGX revenue forecast at $317,825,375,828.
In 2027, ARGX is forecast to generate $359,411,268,496 in revenue, with the lowest revenue forecast at $326,158,741,080 and the highest revenue forecast at $404,723,266,091.